$Berkshire Hathaway(BRK.B)$ Short answer: the rally is mostly a re-rating of the post-Buffett story plus a capital-allocation shift, not an earnings upgrade — and at ~1.57x book, just 0.25% below its 52-week high, the easy part of that re-rating has already happened. Sustainability now depends on the 7 November Q3 report confirming that operating profit and buybacks hold up at these prices.
Note on the level:
Berkshire Hathaway (BRK.B)
watchlist
is quoted at $548.56 on 2026-10-27, +1.17% on the day, but the record high on record is $549.96 (2026-10-22) — so it is 0.25% below the peak, not above it. It sits at the 98th percentile of its 52-week range ($464.01–$549.96).
What is actually driving it
1. The "Buffett departure discount" is unwinding. The previous all-time high was set on 2025-05-02, right around Buffett's retirement announcement; the stock then fell for months as investors fretted about the succession. Breaking that level is being read as the market endorsing Greg Abel's leadership
Tiger News
Tiger News
. Abel took over as CEO on 2026-01-01 and Buffett stepped down as chairman on 2026-09-18, handing that role to Howard Buffett — so the governance transition is now essentially complete
Xueqiu
.
2. Abel has visibly changed the capital-allocation posture. In Q2 2026 Berkshire ended 14 consecutive quarters of net equity selling, buying $23.5bn and selling $3.7bn — about $19.8bn net — plus ~$4.5bn of buybacks (the largest quarter in about five years), ~$9.4bn for OxyChem and $6.8bn for Taylor Morrison
Xueqiu
Xueqiu
. Cash fell ~4% to roughly $364.7bn, the first sequential decline in four years
Xueqiu
. Operating profit rose 16% YoY to $12.98bn, with manufacturing/retail +24%, energy +27% and BNSF +6%; insurance underwriting was the weak spot, down 13%
Xueqiu
.
3. The Alphabet stake gave it an AI-linked leg. Alphabet is now a top-five holding (~$37.8bn across A and C shares at end-June), built partly via a $10bn private placement at a 6.5% discount that Abel negotiated
Xueqiu
Xueqiu
. That has softened the "value-only, missed the tech era" framing.
4. Rotation into defensive quality. The stock is +10.2% over the past month and +9.0% over 20 sessions, while the report notes the Nasdaq/S&P and AI names have been correcting — consistent with money rotating toward a cash-rich, low-beta compounder
Xueqiu
.
Is it sustainable?
The bull case is structural rather than momentum: ~$365bn of cash and Treasuries is roughly a third of total assets, earnings are diversified across insurance, rail, energy and retail, and the buyback is price-discretionary (management only repurchases when it judges the stock below intrinsic value)
Xueqiu
Xueqiu
. That gives a valuation floor of sorts and a large optionality on any market dislocation.
The constraint is price. At $548.56 the shares trade at 1.57x book (book value ~$535.60/share, i.e. only ~2.4% above stated net assets), 13.7x TTM EPS of $39.97 and 3.05x sales, with ROE of 12.1%. Two things follow:
Buyback support likely fades here. Berkshire repurchased ~7.14m B-shares in June at an average ~$487.98
Xueqiu
. With the stock now ~12% above that level and at a fresh high, the same price discipline that drove the Q2 buyback argues against large-scale repurchases at current levels — one report explicitly flags this
Xueqiu
. The very flow that helped the stock is self-limiting.
The earnings optics are flattered. H1 net income of $357.7bn... more precisely $35.77bn, +110.8% YoY, was driven mainly by ~$15.6bn of unrealized equity gains and an easy comparison against last year's Kraft Heinz write-down — management itself warns not to read GAAP net income as operating performance
Xueqiu
Xueqiu
. Q2's headline doubling is not an operating-earnings doubling.
Sell-side coverage is thin and lukewarm: 5 analysts, 40% buy / 60% hold, mean target ~$490 (range $313–$628), i.e. the consensus mean sits below the current price. That is a small sample and stale (last updated May 2026), so treat it as sentiment context rather than a valuation anchor. UBS has reportedly lifted its target to $595
Xueqiu
.
What would validate the move: the 2026-11-07 Q3 report showing (a) operating earnings growth continuing without the investment-gain boost, (b) insurance underwriting stabilising after the -13% Q2, and (c) buyback dollars still meaningful at these prices. What would break it: a Q3 in which operating profit stalls while the stock is priced at a book-value premium near its historical top, or a market-wide risk-on rotation that pulls money back out of defensives — the stock's ~9% 12-month gain has been driven by a sharp recent burst rather than steady compounding.
Information is for reference only and does not constitute investment advice. Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments